Search
Avadel Pharmaceuticals PLC
AVDLAdd to Watchlist
21.326USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.12BMarket Cap
LossP/E TTM
More Details of Avadel Pharmaceuticals PLC Company
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Avadel Pharmaceuticals PLC Info
Ticker SymbolAVDL
Company nameAvadel Pharmaceuticals PLC
IPO dateFeb 21, 2088
CEODivis (Gregory J)
Number of employees188
Security typeOrdinary Share
Fiscal year-endFeb 21
AddressBlock 10-1 Blanchardstown Corporate Park
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code15
Phone35319015201
Websitehttps://www.avadel.com/
Ticker SymbolAVDL
IPO dateFeb 21, 2088
CEODivis (Gregory J)
Company Executives of Avadel Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Geoffrey M. Glass
Mr. Geoffrey M. Glass
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Avadel Pharmaceuticals PLC?
The top five shareholders of Avadel Pharmaceuticals PLC are: Dr. Eric J. Ende, M.D.
How many institutions hold shares of Avadel Pharmaceuticals PLC (AVDL)?
As of 2026Q1, 161 institutions hold shares of Avadel Pharmaceuticals PLC, with a combined market value of approximately 1.06M, accounting for 1.08% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -32773385.00.
What is the biggest source of revenue for Avadel Pharmaceuticals PLC?
In 2026Q1, the Vazculep business generated the highest revenue for Avadel Pharmaceuticals PLC, amounting to 10.43M and accounting for 46.70% of total revenue.